scholarly journals Risk of long term renal impairment and duration of follow up recommended for Henoch-Schonlein purpura with normal or minimal urinary findings: a systematic review

2005 ◽  
Vol 90 (9) ◽  
pp. 916-920 ◽  
Author(s):  
H Narchi
Keyword(s):  
Systematic Review ◽  
Renal Impairment ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

scholarly journals Renal Outcomes of Childhood IgA Nephropathy and Henoch Schönlein Purpura Nephritis

2021 ◽  
Vol 73 (10) ◽  
pp. 687-694
Author(s):  
Thanaporn Chaiyapak ◽  
Anirut Pattaragarn ◽  
Suroj Supavekin ◽  
Nuntawan Piyaphanee ◽  
Kraisoon Lomjansook ◽  
...  
Keyword(s):  
Iga Nephropathy ◽  
Complete Recovery ◽  
Clinicopathological Characteristics ◽  
Henoch Schonlein Purpura ◽  
Renal Outcomes ◽  
Nephritic Syndrome ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

Background: Henoch-Schönlein purpura nephritis (HSPN) is considered the systemic form of IgA nephropathy (IgAN). However, differing clinicopathological features and renal outcomes of children with IgAN and HSPN have been reported in some studies. Methods: This study retrospectively reviewed children with IgAN and HSPN younger than 18 years, between January 2004 and December 2015. The clinicopathological characteristics at diagnosis and the renal outcomes after at least 1 year of follow-up were compared between the two groups. Results: A total of 54 children, comprising 21 with IgAN and 33 with HSPN, were recruited. The children with HSPN were younger than the children with IgAN. Gross hematuria and nephritic syndrome at the initial presentation were more common in children with IgAN. Regarding the pathological findings, IgAN had greater chronicity than HSPN. After a median follow-up period from first presentation to renal outcomes measurement of 4.0 years (1.3-12.2) in children with IgAN and 4.2 years (1.1-11.4) in children with HSPN, the renal outcomes were better in the latter group. The incidence of chronic kidney disease (CKD) was 28.6% in children with IgAN and 6.1% in children with HSPN (p = 0.02). Complete recovery was observed more frequently in children with HSPN than in children with IgAN (57.1% in IgAN vs. 87.9% in HSPN, p = 0.01). Conclusions: Childhood IgAN has greater chronicity and worse renal outcomes than childhood HSPN, with a lower rate of complete recovery and a higher frequency of CKD. We recommend long-term follow-up for CKD in children with IgAN.

scholarly journals Renal transplantation in adults with Henoch-Schonlein purpura: long-term outcome

2008 ◽  
Vol 23 (9) ◽  
pp. 3010-3016 ◽  
Author(s):  
G. Moroni ◽  
B. Gallelli ◽  
A. Diana ◽  
A. Carminati ◽  
G. Banfi ◽  
...  
Keyword(s):  
Renal Transplantation ◽  
Henoch Schonlein Purpura ◽  
Term Outcome ◽  
Long Term Outcome ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

scholarly journals Adjuvant treatments for Henoch-Schönlein purpura nephritis in children: A systematic review

2009 ◽  
Vol 70 (3) ◽  
pp. 254-265 ◽  
Author(s):  
Marco Zaffanello ◽  
Milena Brugnara ◽  
Massimo Franchini ◽  
Vassilios Fanos
Keyword(s):  
Systematic Review ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

scholarly journals Effects of Corticosteroid on Henoch-Schonlein Purpura: A Systematic Review

PEDIATRICS ◽  
2007 ◽  
Vol 120 (5) ◽  
pp. 1079-1087 ◽  
Author(s):  
P. F. Weiss ◽  
J. A. Feinstein ◽  
X. Luan ◽  
J. M. Burnham ◽  
C. Feudtner
Keyword(s):  
Systematic Review ◽  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

scholarly journals Preliminary experience with tacrolimus in managing Henoch-Schönlein purpura featuring extrarenal symptoms refractory to conventional therapy

2020 ◽  
Author(s):  
Yan Chen ◽  
Haitao Bai ◽  
Yang Yang ◽  
Zhulan Lian
Keyword(s):  
Adverse Reaction ◽  
Multiple Organ ◽  
Screening Tests ◽  
Henoch Schonlein Purpura ◽  
Open Label ◽  
Organ Systems ◽  
Tacrolimus Therapy ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

Abstract Background Henoch-Schönlein purpura (HSP) is the commonest vasculitis of childhood, affecting multiple organ systems. The extrarenal manifestations are prominent in some HSP cases, for which no standard treatment is available. It is interesting to examine the value of tacrolimus in such cases. Findings Seventeen children received tacrolimus to manage their refractory extrarenal symptoms of HSP in an open-label prospective study. Tacrolimus was administered at daily dose of 0.05–0.15 mg/kg. Tacrolimus was effective in all cases after treatment for 7–21 days. Tacrolimus treatment resulted in complete resolution of extrarenal symptoms in 15 cases, and partial resolution in the remaining 2 cases. During follow-up, skin purpura reoccurred in 2 cases, abdominal pain and loss of follow-up in 1 case each. Drug-related adverse reaction was not observed in any case. Abnormal renal function test was identified in 7 patients by urinary screening tests before tacrolimus therapy, 4 of them received renal biopsy. Only one patient showed evidence of renal impairment during follow-up. Conclusions Tacrolimus works quickly without drug-related adverse reaction in managing the HSP patients featuring recurrent extrarenal symptoms. Our preliminary experience suggests good clinical efficacy and safety of tacrolimus in such off-label use.

Outcome of Henoch-Schönlein purpura nephritis treated with long-term immunosuppression

2007 ◽  
Vol 22 (10) ◽  
pp. 1717-1722 ◽  
Author(s):  
Mohan Shenoy ◽  
Mark G. Bradbury ◽  
Malcolm A. Lewis ◽  
Nicholas J. A. Webb
Keyword(s):  
Henoch Schonlein Purpura ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura ◽  
Purpura Nephritis

Childhood vasculitis

Rheumatology ◽  
2020 ◽  
Vol 59 (Supplement_3) ◽  
pp. iii95-iii100
Author(s):  
Seza Ozen ◽  
Erdal Sag
Keyword(s):  
Early Childhood ◽  
Kawasaki Disease ◽  
Henoch Schonlein Purpura ◽  
Childhood Vasculitis ◽  
Schonlein Purpura ◽  
Henoch Schönlein Purpura

Abstract Vasculitis is a challenging disease for paediatricians. Certain vasculitides are quite common in children whereas others are much rarer compared with adults. The most common vasculitides in childhood are IgA-associated vasculitis (Henoch–Schönlein purpura) and Kawasaki disease, which are usually self-limiting vasculitides although children do develop complications as a result. We now have much better knowledge of how to manage these patients and prevent the deleterious complications. This review provides an up-to-date discussion on childhood vasculitides, including diagnosis, treatment and follow-up strategies, together with a comparison with vasculitides in adults. It also discusses the newly defined monogenic vasculitides that often present during early childhood.

Sign in / Sign up

Export Citation Format

Share Document